Navigation Links
Lexicon to Present Research Results at American Chemical Society Meeting Regarding Target of LX1031 Drug Candidate
Date:8/19/2007

cancer, immune system disorders and ophthalmic disease. To advance the development and commercialization of its programs, Lexicon is working both independently and through collaborators including Bristol-Myers Squibb Company, Genentech, Inc. and N.V. Organon. For additional information about Lexicon and its programs, please visit http://www.lexpharma.com.

Safe Harbor Statement

This press release contains "forward-looking statements," including statements relating to Lexicon's clinical development of LX1031 and the potential therapeutic and commercial potential of LX1031. This press release also contains forward-looking statements relating to Lexicon's growth and future operating results, discovery and development of products, strategic alliances and intellectual property, as well as other matters that are not historical facts or information. All forward-looking statements are based on management's current assumptions and expectations and involve risks, uncertainties and other important factors, specifically including those relating to Lexicon's ability to successfully conduct clinical development of LX1031 and preclinical and clinical development of its other potential drug candidates, advance additional candidates into preclinical and clinical development, obtain necessary regulatory approvals, achieve its operational objectives, obtain patent protection for its discoveries and establish strategic alliances, as well as additional factors relating to manufacturing, intellectual property rights, and the therapeutic or commercial value of its drug candidates, that may cause Lexicon's actual results to be materially different from any future results expressed or implied by such forward-looking statements. Information identifying such important factors is contained under "Factors Affecting Forward-Looking Statements" and "Risk Factors" in Lexicon's annual report on Form 10-K for the year ended December 31
'/>"/>

SOURCE Lexicon Pharmaceuticals, Inc.

Copyright©2007 PR Newswire.

Page: 1 2 3

Related medicine technology :

1. Lexicon Develops Antibodies That Lower Triglycerides and Cholesterol as Potential New Therapy for Heart Disease
2. Lexicon Pharmaceuticals and Fox Chase Publish Findings on Immune Deficiency
3. Lexicon-Genentech Collaboration Yields Potential Therapeutic Targets
4. The Past, Present and Future of HLA Typing
5. Sygnis Pharma AG announces date for presentation of clinical results
6. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
7. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
8. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
9. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
10. Generex Biotechnology to Make Presentations At 46th Annual Meeting of the European Society of Pediatric Endocrinology
11. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... EHE International, the recognized leader in preventive medicine and annual ... David Abrams M.D . in Tarzana, CA ... Through David Abrams M.D ., EHE members in the ... to EHE,s preventive care programs to help proactively maintain their ... Abrams M.D. to its growing private provider network. With Dr. ...
(Date:9/16/2014)... 16, 2014  Decision Resources Group finds that the rheumatoid arthritis ... 2013 to over $18.2 billion in 2023 in the ... Germany , Italy , Spain ... Japan . TNF-alpha inhibitors will remain the leading drug ... but growth will be constrained and patient shares will decline due ...
(Date:9/16/2014)... DUBLIN , Sept. 16, 2014 ... addition of the "Global Laparoscopy Devices Industry ... The Global Laparoscopy Devices Industry Report ... the current state of the global laparoscopic devices. ... of the industry including definitions, classifications, applications and ...
Breaking Medicine Technology:EHE International Certifies David Abrams M.D. as Its Newest Partner 2The Rheumatoid Arthritis Drug Market Will Grow to $18.2 Billion in 2023, Driven by the Uptake of Oral Jak Inhibitors and Non TNF-alpha Biologics 2The Rheumatoid Arthritis Drug Market Will Grow to $18.2 Billion in 2023, Driven by the Uptake of Oral Jak Inhibitors and Non TNF-alpha Biologics 3Global Laparoscopy Devices Industry Report 2014 2
(Date:9/16/2014)... the University of California, San Diego School of Medicine ... assess the safety and efficacy of a new monoclonal ... most common form of blood cancer in adults. ... used by embryonic cells during early development and exploited ... the latter responsible for 90 percent of all cancer-related ...
(Date:9/16/2014)... LINCOLN, R.I. (PRWEB) September 16, 2014 ... from Sunday, Sept. 14, through Saturday, Sept. 20, ... make sure children are safe and secure while in ... from the National Traffic Highway Safety Administration (NHTSA), ... did not read the instruction manual when installing child ...
(Date:9/16/2014)... 16, 2014 CarePoint Health is ... Leigh Montes, MD, has joined our expanded Bariatric ... Hospital. Our system welcomes Dr. Montes to the ... surgical weight loss center, helps patients achieve long-term ... surgery procedures, including Gastric Sleeve, Gastric Bypass, LAP-BAND ...
(Date:9/16/2014)... Pittsburgh, PA (PRWEB) September 16, 2014 ... recovering well today after undergoing successful heart transplantation surgery ... , Mr. Tekulve, who spent most of his 16-year ... the team as a commentator for Root Sports Pittsburgh, ... his transplant surgeon, Stephen Bailey, MD, surgical director of ...
(Date:9/16/2014)... (HealthDay News) -- Illegal drug use among teens in the ... federal report. Encouragingly, the new study also found ... products among young people between the ages of 12 and ... survey of 70,000 people aged 12 and older across the ... or abuse problems among this age group also dropped from ...
Breaking Medicine News(10 mins):Health News:Novel drug targeting leukemia cells enters clinical trial 2Health News:Amica Offers Tips During Child Passenger Safety Week 2Health News:Top Bariatric Surgeon Joins CarePoint Health 2Health News:Top Bariatric Surgeon Joins CarePoint Health 3Health News:Former Pittsburgh Pirates Pitcher and Baseball Analyst Kent Tekulve Undergoes Successful Heart Transplant at Allegheny General Hospital 2Health News:Former Pittsburgh Pirates Pitcher and Baseball Analyst Kent Tekulve Undergoes Successful Heart Transplant at Allegheny General Hospital 3Health News:Fewer U.S. Teens Using Illegal Drugs and Alcohol, Report Finds 2
... Chemo-radiation therapy looks to kill cells on organ,s surface, ... (HealthDay News) -- Patients are being recruited for a ... protocol for pleural mesothelioma, a cancer of the lung,s ... , Currently, the standard treatment is to remove the ...
... how the nervous system and the immune system interact, scientists at The ... which the brain and the spleen communicate. , ... Manhasset, NY (PRWEB) ... nervous system and the immune system interact, scientists at The Feinstein ...
... T. Kennedy DSc, Dean of Tufts University,s Gerald J. ... Policy announced the 3rd Annual Friedman School Symposium, a ... facing industry, policy-makers, academics and thought leaders in the ... September 24th to 26th, 2008. , Fifteen experts will ...
... for Advanced Medical,Education (IAME) announces the release of ... program. Produced in response to a,strong demand by ... 3 CME,credits required for Mammography Center accreditation., ... course,available online at the CME Center of IAME,s ...
... 15 Percent Increase in Prescription Drug,Costs in ... HealthLeaders-InterStudy, NASHVILLE, Tenn., July 21 ... intelligence, reports that Excellus,BlueCross BlueShield will continue ... and public education efforts. According to the,new ...
... (SPI) has,received an R&D contract award from the ... drug candidate for hearing regeneration. SPI has,developed a ... inner ear of mammals involving p27Kip1, a cyclin ... division or proliferation in,many developing cells and tissues ...
Cached Medicine News:Health News:Lung Cancer Trial Targets Asbestos-Related Disease 2Health News:Embargoed Until Monday, July 21 at 5 p.m. EST; Scientists Figure Out How the Immune System and Brain Communicate to Control Disease 2Health News:Embargoed Until Monday, July 21 at 5 p.m. EST; Scientists Figure Out How the Immune System and Brain Communicate to Control Disease 3Health News:'Nutrition Agenda 2008' is focus of Tufts Friedman School Symposium 2Health News:'Nutrition Agenda 2008' is focus of Tufts Friedman School Symposium 3Health News:New York's Excellus BlueCross BlueShield to Continue Generic Medication Promotion to Help Control Costs 2Health News:Sound Pharmaceuticals Receives Additional DoD Funding for Its Hearing Regeneration Product 2
the LabOne Healthcare Group markets laboratory testing to physicians, patients, managed care companies, self-insured employers, wellness companies and hospitals....
... ideal hemostatic gauze for a variety of inpatient ... iX is easy to handle and can be ... sites that are often a challenge faced by ... used to control bleeding in outpatient procedures such ...
Sharp tipped straight scissors. For cutting in the iris plane or cutting peripheral membranes. May also be useful in ROP cases....
Microscissors : Horizontal Scissors...
Medicine Products: